| Time/Date | Headline |
|---|---|
| 28 Jul 2025 | Result of General Meeting |
| 2 Jul 2025 | Proposed Cancellation |
| 1 Jul 2025 | Funding Update |
| 1 Jul 2025 | Result of AGM |
| 30 Jun 2025 | Funding and Operational Update, Delay in Results |
| 11 Jun 2025 | New Committed Credit Facility |
| 6 Jun 2025 | Funding Update, Notice of AGM |
| 30 May 2025 | Funding Update |
| 30 Apr 2025 | Funding Update |
| 8 Apr 2025 | Termination of Facility |
AIMX:CEL
Celadon Pharmaceuticals plc Share Price
Market Cap£8.0mAs at 30/06/2025
Celadon is a pharmaceutical firm based in the UK that specializes in cultivating top-notch cannabis using indoor hydroponic methods. Its primary focus is on catering to the chronic pain market, while also conducting extensive research on cannabinoids in the tightly regulated UK market.
Recent RNS announcements
Company details
| Industry: | Health Care |
| Sector: | Health Care |
| Region: | Europe |
| Admission date: | 19 Oct 2018 |
| Website: | celadonpharma.co.uk |
| Twitter: | @CeladonPlc |
Instrument details
| ISIN: | GB00BDQYGP38 |
| Exchange: | AIMX |
| Market: | Aim |
| Market Segment: | ASQ1 |
| Market Sector: | AMQ1 |
Results & reports
| 3 Jun 2024 | Publication of Annual Report & Notice of AGM |
| 14 May 2024 | Final Results |